| 8/25/2021 |
Known Medicine Raises $7.2 Million Seed Round to Advance Data First Approach to Organoid Technology |
Business Wire |
... and others. This funding will enable Known Medicine to rapidly grow its proprietary 3D cell culture data set for deployment in partnership with biopharmaceutical companies and in the clinical diagnostics space. Known Medicine’s Oncology Diagnostics Inference Network (ODIN TM ) Platform uses proprietary organoid models called M3DUSA TM Models and a bespoke image analysis pipeline - IRIS TM Analysis to predict how well a patient’s tumor will respond to a ... |
| 8/4/2021 |
U.S. $15.98 Billion Cancer Biopsy Markets, 2021-2028: Transition of Novel Oncology Diagnostics from Bench to Clinics & Advancements in Quality and Payment Pertaining to Genetic Cancer Tests |
PR Newswire |
... and Scope Chapter 2 Executive Summary Chapter 3 Market Variables, Trends, and Scope 3.1 Cancer Medical Tourism Within & Outside the U.S. 3.2 Market Driver Analysis 3.2.1 Advent of liquid biopsy 3.2.2 Transition of novel oncology diagnostics from bench to clinics 3.2.3 Advancements in quality and payment pertaining to genetic cancer tests 3.3 Market Restraint Analysis 3.3.1 Risks associated with biopsy procedures 3.3.2 Technical and clinical challenges 3.4 Market Opportunity Analysis ... |
| 7/20/2021 |
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman |
Yahoo News |
Expanded Board to build on company’s recent successes in oncology diagnostics and COVID-19 testingSAN DIEGO, July 20, 2021 --( BUSINESS WIRE )--Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to its Board of Directors, effective immediately. The company also named Director Samuel D. Riccitelli as Chairman of the Board, succeeding long-time Chair David Hale and ... |
| 7/20/2021 |
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman | Business Wire |
Business Wire |
... M. Faye Wilson, both of whom remain Directors.Rubinstein and Morales each brings extensive financial expertise and leadership experience to the Board, supporting Biocept’s focus on strategic growth and the advancement of its oncology diagnostics franchise. With these two additions, Biocept’s Board will increase from seven Directors to nine.“We are proud to expand and strengthen our Board of Directors with these new appointments, which we believe will ... |
| 7/20/2021 |
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman |
digitalmedianet.com |
Published Date: July 20, 2021Expanded Board to build on company’s recent successes in oncology diagnostics and COVID-19 testingSAN DIEGO–(BUSINESS WIRE)–Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has appointed Linda Rubinstein and Antonino Morales to its Board of Directors, effective immediately. The company also named Director Samuel D. Riccitelli as Chairman of the Board, succeeding long-time Chair ... |
| 7/20/2021 |
Biocept Welcomes Linda Rubinstein and Antonino Morales to Board of Directors, Names Director Samuel Riccitelli as Chairman | Financial Buzz |
financialbuzz.com |
... M. Faye Wilson, both of whom remain Directors.Rubinstein and Morales each brings extensive financial expertise and leadership experience to the Board, supporting Biocept’s focus on strategic growth and the advancement of its oncology diagnostics franchise. With these two additions, Biocept’s Board will increase from seven Directors to nine.“We are proud to expand and strengthen our Board of Directors with these new appointments, which we believe will ... |
| 7/2/2021 |
Continuing Medical Education Market Size to Reach Revenues of USD 11.57 Billion by 2026 – Arizton |
inyoregister.com |
... expected to reach an incremental growth of more than USD 1 billion.3. The oncology segment dominated the market and is expected to grow at an incremental growth of more than USD 600 million. Oncology diagnostics is considered as one of the demanding programs among physicians.4. NPOs/physicians organizations dominated the provider’s market. However, the publishing/educational companies are expected to grow with the highest CAGR of 7.77 ... |
| 7/2/2021 |
The global continuing medical education market siz |
wapakdailynews.com |
... expected to reach an incremental growth of more than USD 1 billion.3. The oncology segment dominated the market and is expected to grow at an incremental growth of more than USD 600 million. Oncology diagnostics is considered as one of the demanding programs among physicians.4. NPOs/physicians organizations dominated the provider’s market. However, the publishing/educational companies are expected to grow with the highest CAGR of 7.77 ... |
| 7/2/2021 |
Deer Park Tribune |
dptribune.com |
... expected to reach an incremental growth of more than USD 1 billion.3. The oncology segment dominated the market and is expected to grow at an incremental growth of more than USD 600 million. Oncology diagnostics is considered as one of the demanding programs among physicians.4. NPOs/physicians organizations dominated the provider’s market. However, the publishing/educational companies are expected to grow with the highest CAGR of 7.77 ... |
| 6/30/2021 |
This Explosive Biotech Is Taking On a Huge New Market |
MSN |
... frame. The $10.25 billion med-tech company, which honed its diagnostics craft on non-invasive blood testing to screen for fetal genetic abnormalities such as Down syndrome, is now starting to gain traction in oncology diagnostics -- the turf of Guardant Health (NASDAQ: GH) and ARK Genomic Revolution ETF holding Adaptive Biotechnologies (NASDAQ: ADPT) .Demonstrated ability to expand Natera's testing volume in its non-invasive reproductive health segment has grown every ... |
| 6/30/2021 |
This Explosive Biotech Is Taking On a Huge New Market |
fool.com |
... frame. The $10.25 billion med-tech company, which honed its diagnostics craft on non-invasive blood testing to screen for fetal genetic abnormalities such as Down syndrome, is now starting to gain traction in oncology diagnostics -- the turf of Guardant Health (NASDAQ: GH) and ARK Genomic Revolution ETF holding Adaptive Biotechnologies (NASDAQ: ADPT) .Natera's testing volume in its non-invasive reproductive health segment has grown every year since 2013 -- from ... |
| 6/30/2021 |
This Explosive Biotech Is Taking On a Huge New Market | The Motley Fool |
fool.com |
... frame. The $10.25 billion med-tech company, which honed its diagnostics craft on non-invasive blood testing to screen for fetal genetic abnormalities such as Down syndrome, is now starting to gain traction in oncology diagnostics -- the turf of Guardant Health ( NASDAQ:GH ) and ARK Genomic Revolution ETF holding Adaptive Biotechnologies ( NASDAQ:ADPT ) .Demonstrated ability to expand Natera's testing volume in its non-invasive reproductive health segment has grown every ... |
| 6/28/2021 |
Medical Imaging Technologies for Oncology Diagnostics Market Analysis by Trends, Types, Applications, manufactures, Regions, Market size and Forecast up to 2023 |
fnbherald.com |
Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2582547&source=atmImportant Key questions answered in Medical Imaging Technologies for Oncology Diagnostics market report:What will the market growth rate, Overview, and Analysis by Type of Medical Imaging Technologies for Oncology Diagnostics in 2024?What are the key factors affecting market dynamics? What are the drivers, challenges, and business risks in Medical Imaging Technologies for Oncology Diagnostics market?What ... |
| 5/16/2021 |
Immunoscore is now available in Rectal Cancer for expert |
Globe Newswire |
Immunoscore® is now available in Rectal Cancer for expert clinical centers through an Innovation Access Program May 11, 2021 08:00 ET HalioDx Marseille, FRANCE Immunoscore® heads up to become the standard precision tool for the “Watch and Wait” strategy in locally advanced rectal cancer Expert clinical centers already involved worldwide in this new Innovation Access Program Marseille, France, May 11, 2021 - HalioDx SAS, the immuno-oncology diagnostics ... |
| 5/15/2021 |
Exact Sciences' First-Quarter Results Show Its Strength Under Pressure |
fool.com |
... still able to post 10% year-over-year quarterly sales growth for Cologuard.IMAGE SOURCE: GETTY IMAGES.Precision oncology fell short It's unlikely that the $16.8 billion market-cap company's late 2019 purchase of oncology diagnostics player Genomic Health has been as fruitful as management hoped it would be. Exact Sciences' sales in precision oncology for the quarter came in at $129 million, a measly 1% increase from year-ago ... |
| 5/15/2021 |
Exact Sciences' First-Quarter Results Show Its Strength Under Pressure |
newsbreak.com |
... headwinds, the company was still able to post 10% year-over-year quarterly sales growth for Cologuard.Precision oncology fell short It's unlikely that the $16.8 billion market-cap company's late 2019 purchase of oncology diagnostics player Genomic Health has been as fruitful as management hoped it would be. Exact Sciences' sales in precision oncology for the quarter came in at $129 million, a measly 1% increase from year-ago ... |
| 4/27/2021 |
Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center |
healthcareimc.com |
Posted on April 27, 2021 by Elaine HuesingTORONTO , April 27, 2021 /CNW/ – Geneseeq Technology Inc. (“Geneseeq”), a precision oncology diagnostics company, and AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN), a global biopharmaceutical company, are excited to announce their strategic collaboration to establish a Bio-Diagnostic Innovation Center in Guangzhou, China . The center is expected to initiate an integrative and patient-centric program where disease diagnosis, treatment, and ... |
| 4/27/2021 |
Geneseeq and AstraZeneca Collaborate to Build Guangzhou Bio-Diagnostics Innovation Center |
PR Newswire |
TORONTO , April 27, 2021 /PRNewswire/ - Geneseeq Technology Inc. ("Geneseeq"), a precision oncology diagnostics company, and AstraZeneca (LSE: AZN) (STO: AZN) (Nasdaq: AZN ), a global biopharmaceutical company, are excited to announce their strategic collaboration to establish a Bio-Diagnostic Innovation Center in Guangzhou, China . The center is expected to initiate an integrative and patient-centric program where disease diagnosis, treatment, and rehabilitation coexist. The center will combine Geneseeq's expertise in developing ... |
| 4/7/2021 |
Invitae to acquire Genosity for $200m, lands $1.15bn investment |
medicaldevice-network.com |
... products, which are designed to enable development and deployment of complex sequencing-based tests, to Invitae’s platform.Invitae said the deal will accelerate the time to market and decentralisation of Invitae’s personalised oncology diagnostics , which include three devices under development that have received breakthrough device designation from the US (FDA).Genosity has already worked with Invitae on a number of projects and clinical research trials in the past ... |
| 3/30/2021 |
Biocept (NASDAQ:BIOC) Announces Quarterly |
Daily Political |
... the stock. Zacks Investment Research downgraded Biocept from a “hold” rating to a “sell” rating in a research report on Monday, January 4th. Biocept Company Profile Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a ... |